Bionano Genomics (BNGO) Cash from Financing Activities (2017 - 2026)

Bionano Genomics has disclosed Cash from Financing Activities across 10 years of filings, most recently posting $657000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $657000.0, down 93.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.8 million (down 26.66% YoY), and the FY2025 annual result was $24.0 million, up 275.66% from the prior year.
• Cash from Financing Activities came in at $657000.0 for Q1 2026 at Bionano Genomics, down from $1.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $68.5 million in Q4 2023 to a low of -$21.6 million in Q1 2024.
• The 5-year median for Cash from Financing Activities is $3.9 million (2024), against an average of $8.7 million.
• Across the five-year window, Cash from Financing Activities jumped 212214.29% in 2023 and plunged 245.46% in 2024, its largest moves.
• Bionano Genomics' Cash from Financing Activities stood at $146000.0 in 2022, then jumped by 46806.85% to $68.5 million in 2023, then slumped by 94.32% to $3.9 million in 2024, then sank by 58.79% to $1.6 million in 2025, then slumped by 59.01% to $657000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $657000.0 (Q1 2026), $1.6 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.